Our Goals

We are dedicated to finding new ways to support people living with neurodevelopmental conditions. Our mission is to test treatments that may improve symptoms and overall quality of life.

To ensure our research meets the highest possible standards, we work closely with world-leading experts and organisations, including:

• Industry Partners (leading pharmaceutical and biotech companies)
• King’s Clinical Trials Unit and the KHP Clinical Trials Office
• NIHR Maudsley Biomedical Research Centre
• NIHR / Wellcome Trust King's Clinical Research Facility

What We Focus On

The Neurodevelopmental Conditions Clinical Trials Centre (NDC-CTC) supports clinical trials of potential treatments from early to late phase trials. Our trained raters can assess cognitive and adaptive functioning (including WAIS, WASI, Vineland, and KBIT tests), and conduct specialist assessments for Alzheimer’s disease, mental health conditions and autism.

Our centre has access to EEG, MR and PET scans, and clinical staff can undertake lumber punctures and blood draws for biomarker studies, This means our studies are robust and can provide clear, reliable results.

We often use findings from experimental studies within the department to identify the most promising options in our clinical trials pipeline. These studies allows us to check if a treatment can create a measurable change in the brain or behaviour before moving to a full-scale trial.

We offer trials for individuals with:

• Autism spectrum conditions
• Down syndrome, including for Alzheimer’s Disease
• Fragile X syndrome
• Phelan-McDermid Syndrome and other rare neurodevelopmental genetic conditions